



## Wendy Kan

Counsel

Hong Kong

D: +852-3512-2321

wkan@omm.com

Wendy Kan focuses her practice on corporate finance and capital markets. Her experience includes advising on Hong Kong initial public offerings, cross-border mergers and acquisitions, regulatory compliance, and general commercial matters.

## Experience

### ECM Transactions

- OrbusNeich Medical Group in its US\$200 million Series A and A-2 Fundraising Rounds
- Goldman Sachs (Asia) L.L.C. and China International Capital Corporation Hong Kong Securities Limited and other underwriters in the US\$145 million IPO and listing of Shanghai HeartCare Medical Technology Corporation Limited on the Hong Kong Stock Exchange
- Brie Biosciences Limited in its US\$318 million IPO and listing on the Hong Kong Stock Exchange
- Keymed Biosciences Inc. in its US\$398 million IPO and listing on the Hong Kong Stock Exchange
- Fortune Financial Capital as sole sponsor, Fortune Securities, CICC as joint global coordinators and other underwriters in the US\$56.8 million primary listing of Zero2IPO Holdings Inc. on the Hong Kong Stock Exchange
- JACOBIO Pharmaceuticals Group Co., Ltd. in its US\$174 million IPO and listing on the Hong Kong Stock Exchange
- RemeGen Co., Ltd. in its US\$515 million IPO and listing on the Hong Kong Stock Exchange

## Admissions

*Bar Admissions*

Hong Kong

## Education

University of Hong Kong, PCLL; LLB

- Honliv Healthcare Management Group Company Limited in its US\$41.3 million IPO and listing on the Hong Kong Stock Exchange
- Peijia Medical Limited in its US\$343 million IPO and listing on the Hong Kong Stock Exchange
- Shanghai Kindly Medical Instrument Co., Ltd., in its US\$106 million IPO and listing on the Hong Kong Stock Exchange
- Pharmaron in its approximately US\$588 million dual primary listing and H share offering in Hong Kong
- China Securities (International) Corporate Finance Company Limited, as the sole sponsor and lead underwriter, in the US\$133 million IPO of mobile game publisher FingerTango Inc.(6860.HK) on the Hong Kong Stock Exchange
- China Securities (International) Corporate Finance Company Limited, as the sole sponsor and lead underwriter, in the US\$40 million IPO of mobile game publisher Digital Hollywood Interactive Limited (2022.HK) on the Hong Kong Stock Exchange
- Dexin China Holdings Company Limited (2019.HK) in its US\$190 million IPO and listing on the Hong Kong Stock Exchange
- Shanghai Haohai Biological (6826.HK) in its US\$300 million IPO and listing on the Hong Kong Stock Exchange
- Phoenix Healthcare Group Co. Ltd. in its HK\$1.5 billion (US\$190 million) IPO on the Main Board of the Hong Kong Stock Exchange
- Hengxing Gold Holding Company Limited in its HK\$330 million (US\$42.3 million) IPO on the Main Board of the Hong Kong Stock Exchange
- Representing a Beijing based hospital group in its proposed listing on the Main Board of the Hong Kong Stock Exchange

### **Mergers and Acquisitions**

- LifeTech Scientific Corporation in its issuance of convertible notes valued at HK\$2 billion (US\$281 million) as part of the strategic investment by Medtronic, Inc. (a Fortune 500 Company)
- a Korea based entertainment group in the acquisition of the entire equity interest of a Hong Kong private company. The private company is principally engaged in the entertainment business
- a PRC based mining company in the US\$85 million pre-IPO investment by Deutsche Bank AG, Hong Kong Branch
- a shareholder of a NASDAQ-listed company engaging in the business of producing and selling a wide variety of fruit products in its first round of financing through subscription of exchange bonds and preferred shares. The investors include sovereign funds and a state-owned bank

### **DCM Transactions**

- China Eastern Airline in connection with its "dim sum" bond offering of RMB2.2 billion 3.875% guaranteed bonds and a tap issue of RMB800 million 4.8% guaranteed bonds

## **Professional Activities**

### **Member**

- Hong Kong Law Society

**Languages**

- Mandarin Chinese
- Cantonese